SUMO1 and neoplasm: The analysis based on the single-cell PAAD dataset showed that the expression level of SUMO1/2/3 was higher in cancer cells or cancer stem cells and lower in many kinds of tumor-infiltrating immune cells, with the exception of B cells (Figures 1I, J) (Supplementary Figure S1B).